About fifteen years ago a bioeffect modeling study recommended hypofractionation as a potential strategy for improving the therapeutic ratio in prostate cancer. There has been a lot of debate whether hypofractionation is as effective as conventional fractionated radiotherapy. The recent study published in The Lancet suggests that it is as effective. Multiple studies have reported a low α to β ratio for prostate cancer, indicating that hypofractionation could improve the biological tumor dose without increasing genitourinary and gastrointestinal toxicity.
The scientists from the Netherlands have assessed this theory in the phase 3 HYPRO trial for patients with intermediate-risk and high-risk prostate cancer. The group has previously reported acute incidence of genitourinary and gastrointestinal toxicity. In this publication, they have reported data for late genitourinary and…
